减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股拟周五登陆纳斯达克

智通财经04-14

智通财经APP获悉，专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics(KLRA.US)于周一公布其首次公开募股(IPO)条款。这家总部位于马萨诸塞州沃尔瑟姆的企业计划通过发行3330万股股票筹集5亿美元，发行价区间为每股14至16美元。部分股东拟在此次发行中认购价值2.25亿美元的股票，占交易总额的45%。根据计划，Kailera ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2627741817?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-14 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627741817","market":"fut","top_or_hot":-1,"title":"减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics(KLRA.US)于周一公布其首次公开募股(IPO)条款。这家总部位于马萨诸塞州沃尔瑟姆的企业计划通过发行3330万股股票筹集5亿美元，发行价区间为每股14至16美元。部分股东拟在此次发行中认购价值2.25亿美元的股票，占交易总额的45%。根据计划，Kailera ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428212.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-14 15:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1428212.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics(KLRA.US)于周一公布其首次公开募股(IPO)条款。这家总部位于马萨诸塞州沃尔瑟姆的企业计划通过发行3330万股股票筹集5亿美元，发行价区间为每股14至16美元。部分股东拟在此次发行中认购价值2.25亿美元的股票，占交易总额的45%。根据计划，Kailera ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1428212.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JEPQ","symbol_name":"JPMorgan Nasdaq Equity Premium Income ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1428212.html","article_id":"2627741817","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627741817","pubTimestamp":1776151188,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics于周一公布其首次公开募股条款。根据计划，Kailera 预计将于本周四晚间完成最终定价，并于次日在纳斯达克交易所挂牌交易。其核心候选药物ribupatide目前正在全球开展III期临床试验，这是一种每周一次注射的GLP-1/葡萄糖依赖性促胰岛素多肽受体双重激动剂肽。Kailera Therapeutics成立于2024年，计划在纳斯达克上市，股票代码为KLRA。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","QQQ":"纳指100ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","TQQQ":"纳指三倍做多ETF","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QQQA":"ProShares Nasdaq-100 Dorsey Wright Momentum ETF","TQQY":"GraniteShares YieldBOOST QQQ ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","BK4007":"制药","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","SQQQ":"纳指三倍做空ETF","BK4539":"次新股","ONEQ":"Fidelity NASDAQ Composite Index ETF","KLRA":"Kailera Therapeutics, Inc.","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","PSQ":"做空纳斯达克100指数ETF-ProShares","QYLG":"Nasdaq 100 Covered Call & Growth ETF","IYW":"美国科技ETF-iShares","BK1147":"投资银行业与经纪业","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","BK4139":"生物科技","QDTE":"Roundhill N-100 0DTE Covered Call Strategy ETF","FTEC":"Fidelity MSCI Information Techno","NVIW.SI":"NVDA 3xLongSG261006","QQQM":"NASDAQ100指数ETF-Invesco"},"translate_title":"Weight loss drug company Kailera Therapeutics (KLRA.US) IPO priced at $14-16/share to land on Nasdaq on Friday","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/3978cae2a219195b64bb0ea4b8364738","symbols_score_info":{"JEPQ":0.6,"KLRA":1.98,"ONEQ":0.6,"QQQA":0.6,"QID":0.6,"MNQmain":0.6,"QQQ":0.6,"PSQ":0.6,"NVIW.SI":0.6,"QLD":0.6,"IYW":0.6,"FTEC":0.6,"QQQM":0.6,"TQQY":0.6,"SQQQ":0.6,"TQQQ":0.6,"QYLG":0.6,"QQQY":0.6,"QQQJ":0.6,"GPIQ":0.6,"QQQE":0.6,"QDTE":0.6},"content_text":"智通财经APP获悉，专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics(KLRA.US)于周一公布其首次公开募股(IPO)条款。这家总部位于马萨诸塞州沃尔瑟姆的企业计划通过发行3330万股股票筹集5亿美元，发行价区间为每股14至16美元。部分股东拟在此次发行中认购价值2.25亿美元的股票，占交易总额的45%。根据计划，Kailera 预计将于本周四(4月16日)晚间完成最终定价，并于次日在纳斯达克交易所挂牌交易。目前，Kailera正推进四款针对肥胖症的临床阶段候选药物，采用多种基于胰高血糖素样肽-1(GLP-1)的作用机制和给药途径。其核心候选药物ribupatide(又称KAI-9531)目前正在全球开展III期临床试验，这是一种每周一次注射的GLP-1/葡萄糖依赖性促胰岛素多肽受体双重激动剂肽。该公司正在通过开发每日一次的口服片剂制剂——口服ribupatide，来拓展其ribupatide产品系列，该口服制剂基于与注射用ribupatide相同的肽段。值得一提的是，Kailera的核心资产深度绑定其中国背景，全线在研产品均源于与中国制药巨头恒瑞医药的战略合作——2024年，公司从恒瑞医药获得四款GLP-1及相关靶点候选药物在大中华区外的全球开发及商业化权益。当前研发管线中，周效型GLP-1/GIP受体双重激动剂ribupatide作为核心候选药物，其全球III期临床试验进展备受关注，被视为诺和诺德Wegovy与礼来Zepbound的有力潜在竞争者。在剂型拓展上，公司同步推进基于同一肽段的每日一次口服片剂研发，通过更便捷的给药方式切入全球数百亿美元肥胖症市场，形成注射与口服双线并进的产品布局。在财务表现与资本路径方面，Kailera 展现了极强的吸金能力与扩张野心。公司在 2025 年完成了高达 6 亿美元的 B 轮融资，创下当年生物技术行业单笔融资的最高纪录之一。尽管截至 2025 年底，公司账面上仍握有 5.46 亿美元的充裕现金储备，但由于新药研发进入昂贵的临床后期阶段，其 2025 年全年的净亏损达到了 1.49 亿美元。此次赴纳斯达克上市，标志着该公司从初创期向商业化冲刺的关键转折。Kailera Therapeutics成立于2024年，计划在纳斯达克上市，股票代码为KLRA。摩根大通、杰富瑞、Leerink Partners、道明证券和Evercore ISI担任此次交易的联席账簿管理人。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627741817","isCrawlerRequest":true}

减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股 拟周五登陆纳斯达克

精彩评论

减肥药公司Kailera Therapeutics(KLRA.US)IPO定价14-16美元/股拟周五登陆纳斯达克